Stay updated on Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial page
- CheckyesterdayChange DetectedEnd point definitions for EFS and OS were updated to anchor timing to the first dose and specify progression assessment methods; serum TARC biomarker endpoints were removed.SummaryDifference0.4%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe revision label has advanced from v3.6.5 to v3.6.6, indicating a newly published update to the page; this update denotes versioning rather than substantive changes to study details.SummaryDifference0.0%

- Check22 days agoChange DetectedTwo NIH grant entries for 2017 and 2023 were added to the study record, indicating additional U.S. NIH funding support for this trial. This updates the funding context for readers reviewing the study's support sources.SummaryDifference0.1%

- Check36 days agoChange DetectedThe page revision version was updated from v3.6.4 to v3.6.5, signaling a small update to the page's content or metadata.SummaryDifference0.0%

- Check44 days agoChange DetectedThe Plain Language Summary has been removed from the Study Details page, eliminating the lay-friendly overview of the trial’s purpose and design. This shifts the page toward more technical content and may affect how easily non-specialists can understand the study.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4. This reflects a minor internal update with no visible changes to study content or user-facing features.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial page.